Correlation of tumor necrosis factor α (TNFα) with high Caspase 3-like activity in myelodysplastic syndromes

被引:49
作者
Mundle, SD [1 ]
Reza, S [1 ]
Ali, A [1 ]
Mativi, BY [1 ]
Shetty, V [1 ]
Venugopal, P [1 ]
Gregory, SA [1 ]
Raza, A [1 ]
机构
[1] Rush Presbyterian St Lukes Med Ctr, Rush Canc Inst, Chicago, IL 60612 USA
关键词
tumor necrosis factor alpha (TNF alpha); Caspase; 1; 3; apoptosis; inhibition; pentoxifylline; myelodysplastic syndromes (MDS); HL60; cells;
D O I
10.1016/S0304-3835(99)00072-5
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Increased intramedullary apoptotic death of hematopoietic cells is thought to contribute to the ineffective hematopoiesis in myelodysplastic syndromes (MDS). Furthermore, high amounts of tumor necrosis factor alpha (TNF alpha) have previously been correlated with apoptosis in MDS marrows. The present studies were undertaken to examine the status of two key downstream effecters of TNF alpha signaling, i.e. Caspase 1 and Caspase 3 enzymes, using a fluorometric assay in the bone marrow aspirate mononuclear cells (BMMNC) in relation to apoptotic DNA fragmentation detected by in situ end-labeling (ISEL) of DNA and with localization of TNF alpha in the corresponding biopsies from 14 MDS patients. Both Caspase 1 and 3 were detectable in freshly harvested BMMNC, albeit median Caspase 3 levels (47.5 units/mg protein) being almost 10 times higher than Caspase 1 (4.0 units/mg protein). Upon short-term culture for 4 h in a serum-supplemented medium in vitro a significant increase was seen in Caspase 3 activity (58.8 +/- 13.9 at 0 h vs. 177.8 +/- 55.2 units/mg protein at 4 h, n = 14, P = 0.017) and in percent cells labeled by ISEL (apoptotic index or AI%: 0.76% +/- 0.25% vs. 3.99% +/- 1.1%, n = 14, P = 0.004, respectively). Caspase I activity increased after 15 min in culture. Interestingly, TNF alpha levels measured by immunohistochemistry correlated with the net increase in Caspase 3 activity after 4 h (rho = 0.517, n = 13, P = 0.07) and the starting levels of Caspase 1 at 0 h correlated with the Caspase 3 levels attained at 4 h (rho = 0,593, n = 13, P = 0.033). Additionally when TNF alpha-positive bone marrows (8/ 14) were compared with the negative marrows (6/14) the Caspase 3 levels were significantly higher in the TNF alpha-positive marrows (189.6 +/- 66.2 vs. 25.0 +/- 14.6 units/mg protein, respectively, P = 0.043). The increase in AI%, though not statistically significant, was also higher in the TNF alpha-positive marrows. Finally in HL60 cells the effects of different Caspase inhibitors and pentoxifylline (PTX) (interferes with lipid signaling of cytokines) on TNF alpha-induced apoptosis were evaluated. TNF alpha treatment significantly increased AI% (P < 0.003) as compared to the untreated controls. A co-treatment with three Caspase inhibitors, zVAD.FMK (inhibitor of Caspases 1 and 3, 10 mu M/l), Ac.YVAD.FMK (Caspase 1 inhibitor, 1 mu M/l), Ac.DEVD.FMK (Caspase 3 inhibitor, 10 mu M/l) as well as PTX (250 mu M/l) significantly curtailed the AI% induced by TNF alpha The present studies thus identify the downstream effecters of TNF alpha-inducible apoptosis in MDS and so also the suppressors of TNFa apoptotic signaling. These results may have significant clinical implications in the therapy of MDS in the future. (C) 1999 Published by Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:201 / 207
页数:7
相关论文
共 20 条
[1]  
Ali A., 1997, Blood, V90, p521A
[2]   Apoptosis in blood diseases - Review - New data [J].
Binet, JL ;
Mentz, F ;
MerleBeral, H .
HEMATOLOGY AND CELL THERAPY, 1996, 38 (03) :253-264
[3]   CELL-CYCLE PARAMETERS AS BIOLOGICAL PREDICTORS OF PROGNOSIS IN AML - A REVIEW AND UPDATE OF CELL-CYCLE KINETICS AND REMISSION INDUCTION DURATION IN ACUTE-LEUKEMIA [J].
BOKHARI, SAJ ;
ABBAS, A ;
YOUSUF, N ;
MEHDI, A ;
UMERANI, A ;
QADIR, K ;
SHEIKH, Y ;
AKHTAR, S ;
CHUGHTAI, S ;
PREISLER, H ;
RAZA, A .
LEUKEMIA & LYMPHOMA, 1992, 6 (03) :197-207
[4]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[5]   DOWN-REGULATION OF TUMOR-NECROSIS-FACTOR EXPRESSION BY PENTOXIFYLLINE IN CANCER-PATIENTS - A PILOT-STUDY [J].
DEZUBE, BJ ;
SHERMAN, ML ;
FRIDOVICHKEIL, JL ;
ALLENRYAN, J ;
PARDEE, AB .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1993, 36 (01) :57-60
[6]   Sequential activation of ICE-like and CPP32-like proteases during Fas-mediated apoptosis [J].
Enari, M ;
Talanian, RV ;
Wong, WW ;
Nagata, S .
NATURE, 1996, 380 (6576) :723-726
[7]   A role for tumour necrosis factor-α, Fas and Fas-ligand in marrow failure associated with myelodysplastic syndrome [J].
Gersuk, GR ;
Beckham, C ;
Loken, MR ;
Kiener, P ;
Anderson, JE ;
Farrand, A ;
Troutt, AB ;
Ledbetter, JA ;
Deeg, HJ .
BRITISH JOURNAL OF HAEMATOLOGY, 1998, 103 (01) :176-188
[8]   Morphological changes and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoietin [J].
HellstromLindberg, E ;
KanterLewensohn, L ;
Ost, A .
LEUKEMIA RESEARCH, 1997, 21 (05) :415-425
[9]   Apoptosis resistance of blood cells from patients with paroxysmal nocturnal hemoglobinuria, aplastic anemia, and myelodysplastic syndrome [J].
Horikawa, K ;
Nakakuma, H ;
Kawaguchi, T ;
Iwamoto, N ;
Nagakura, S ;
Kagimoto, T ;
Takatsuki, K .
BLOOD, 1997, 90 (07) :2716-2722
[10]   Is apoptosis a massive process in myelodysplastic syndromes? [J].
Lepelley, P ;
Campergue, L ;
Grardel, N ;
Preudhomme, C ;
Cosson, A ;
Fenaux, P .
BRITISH JOURNAL OF HAEMATOLOGY, 1996, 95 (02) :368-371